SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for SNP rs17611

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Nutrition and Physical Activity in Patients With Cerebrovascular Disease

The study will provide evidence of eating habits and physical activity in cerebrovascular patients in Luxembourg and of the degree to which these habits may be changed acutely (after one month) and in the long run (after 4 months) by intensive counselling. Furthermore the influence of intensive counselling and of the consumption of red wine on cerebrovascular risk factors, cognition, and on surrogate parameters for stroke will be assessed.

NCT01146132 Cerebrovascular Disorders Dietary Supplement: Conventional diet +/- wine Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine
MeSH: Cerebrovascular Disorders

The genetic analyses will investigate: A) Profiles of inflammatory, anti-inflammatory cytokines B) Genes related to risk of stroke C) Chromosome regions related to atherosclerosis D) Genetic polymorphism in inflammation Genes to be analyzed: FABP2, MTP1, ApoE, ApoA1, PPAR gamma Pro 12 Ala, TNF alpha, Paraoxonase 1, ADH, Kinesin-like protein (KIF) 6 Trp719Arg (rs20455), SNP, 5 (component of complement 5) 2416A> G variant (rs17611), sCAMs (sICAM-1, sVCAM-1, sPSEL et sESEL), (C3, C4) Complement and CRP, P-selectin and its ligand, P-selectin glycoprotein ligand 1. Inclusion Criteria: - In- and outpatients of the Neurology Department of the CHL and their family members - Carotid atherosclerosis assessed by B-mode ultrasound of at least 20% lumen reduction - No acute stroke/TIA/amaurosis fugax (at least 3 months ago) - Temporal ultrasound window suitable for recording of the middle cerebral artery - Ability to give informed consent Exclusion Criteria: - No signed informed consent - patient not able to give informed consent Inclusion Criteria: - In- and outpatients of the Neurology Department of the CHL and their family members - Carotid atherosclerosis assessed by B-mode ultrasound of at least 20% lumen reduction - No acute stroke/TIA/amaurosis fugax (at least 3 months ago) - Temporal ultrasound window suitable for recording of the middle cerebral artery - Ability to give informed consent Exclusion Criteria: - No signed informed consent - patient not able to give informed consent Cerebrovascular Disorders Cerebrovascular Disorders Quality of life in the elderly and their families is severely affected by stroke and cognitive dysfunction caused by atherosclerosis of the brain supplying arteries.

Primary Outcomes

Description: Assess the influence of intensive counselling and of the consumption of red wine on cerebrovascular risk factors, cognition and on surrogate parameters for cerebrovascular disease.

Measure: Differences in mean systolic blood pressure in the two diet/sport arms

Time: 4 months

Secondary Outcomes

Description: Assess effects on cerebrocardiovascular health profile, cognitive function and ultrasound parameters.

Measure: Effects on cerebrovascular health profile

Time: 4 months

Description: The genetic analyses will investigate: A) Profiles of inflammatory, anti-inflammatory cytokines B) Genes related to risk of stroke C) Chromosome regions related to atherosclerosis D) Genetic polymorphism in inflammation Genes to be analyzed: FABP2, MTP1, ApoE, ApoA1, PPAR gamma Pro 12 Ala, TNF alpha, Paraoxonase 1, ADH, Kinesin-like protein (KIF) 6 Trp719Arg (rs20455), SNP, 5 (component of complement 5) 2416A> G variant (rs17611), sCAMs (sICAM-1, sVCAM-1, sPSEL et sESEL), (C3, C4) Complement and CRP, P-selectin and its ligand, P-selectin glycoprotein ligand 1

Measure: Assessment of genetic marker and/or genetic modifications.

Time: Baseline


HPO Nodes